Benjamin Freedman

Benjamin Freedman is a prominent scientist and entrepreneur specializing in kidney disease research and regenerative medicine using human pluripotent stem cells. He currently serves as the Chief Science Officer at Plurexa, a position he has held since July 2022.1

Academic Background and Career

Dr. Freedman's academic journey includes:

• PhD in Molecular and Cell Biology from the University of California, Berkeley (2003-2009)
• Postdoctoral research in Stem Cells for Kidney Disease at Harvard Medical School (2010-2015)
• BA in Biochemistry and Biology from the University of Pennsylvania (1999-2003)1

His career progression in academia has been notable:

• Associate Professor of Medicine at the University of Washington (July 2020-Present)
• Assistant Professor of Medicine at the University of Washington (July 2015-December 2021)
• Instructor in Medicine at Harvard Medical School (October 2014-June 2015)1

Research Focus

Dr. Freedman's research primarily focuses on:

• Studying human pluripotent stem cells to discover new drugs for kidney disease treatment
• Developing methods to grow new kidney units from patients' own cells
• Modeling polycystic kidney disease using human pluripotent stem cells
• Bioengineering functional human kidney tubules from stem cells12

His laboratory has made significant strides in differentiating human pluripotent stem cells into kidney organoids, creating a "kidney-in-a-dish" prototype.2

Achievements and Recognition

Throughout his career, Dr. Freedman has received several honors and awards, including:

• Mentored Career Development Award from NIH/NIDDK (2014)
• Young Investigator Grant from the National Kidney Foundation (2014)
• National Research Service Award from NIH/NIDDK (2011)1

Professional Goals

Dr. Freedman's career objectives include:

• Making fundamental discoveries in scientific research
• Applying these discoveries to benefit society
• Educating and training other scientists1

His work at Plurexa and the University of Washington continues to advance the field of kidney disease research and regenerative medicine, with potential implications for developing new therapies and treatment approaches.